SNDX Stock: Price, Earnings History and SEC Filings
Syndax Pharmaceuticals, Inc. (SNDX) last traded at $13.65, down 3.53% on the latest session and down 27.4% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.55 against an analyst estimate of $-0.45, a miss of 22.2%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
SNDX earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 4, 2026 | $-0.55 | $-0.45 | -22.22% |
| Mar 2026 | Apr 30, 2026 | $-0.48 | $-0.59 | +18.64% |
| Dec 2025 | Feb 26, 2026 | $-0.78 | $-0.64 | -21.88% |
| Sep 2025 | Nov 3, 2025 | $-0.70 | $-0.74 | +5.41% |
SNDX beat the analyst EPS estimate in 2 of its last 4 reported quarters. Source: Nasdaq.
How SNDX reacts to earnings
Across its last 8 earnings releases, SNDX moved 9.6% on average the next session, in either direction. It rose after 4 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-04 | After close | +4.40% |
| 2026-04-30 | After close | -10.83% |
| 2026-02-26 | After close | +5.03% |
| 2026-01-12 | After close | -1.21% |
| 2025-11-03 | After close | +11.56% |
| 2025-08-04 | After close | +21.10% |
| 2025-05-05 | After close | -21.59% |
| 2025-03-03 | Before open | -1.02% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
SNDX financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $172M | -$285M | -$323M | -165.6% | $-3.29 |
| 2024 | $24M | -$319M | -$275M | -1346.1% | $-3.72 |
| 2023 | $0 | -$209M | -$161M | – | $-2.98 |
| 2022 | $0 | -$149M | -$134M | – | $-2.46 |
| 2021 | $140M | $25M | $29M | 17.8% | $0.46 |
| 2020 | $2M | -$73M | -$71M | -4822.5% | $-1.87 |
| 2019 | $2M | -$56M | – | -3694.6% | $-1.84 |
| 2018 | $2M | -$74M | -$69M | -4875.5% | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for SNDX
- 10-Q · Aug 4, 2026
- 8-K · Aug 4, 2026Results of operations, Financial statements and exhibits
- 8-K · Jul 14, 2026Other events, Financial statements and exhibits
- 8-K · Jun 10, 2026Material agreement, New financial obligation, Unregistered share sale
- 8-K · Jun 10, 2026Officer or director change, Shareholder vote, Financial statements and exhibits
- 8-K · Jun 4, 2026Material agreement, New financial obligation, Unregistered share sale
- DEF 14A · Apr 30, 2026
- 10-Q · Apr 30, 2026
- 8-K · Apr 30, 2026Results of operations, Financial statements and exhibits
- 10-K · Feb 26, 2026
Insider filing activity
SNDX insiders filed 1 Form 4 report in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
SNDX news
- Syndax’s Revuforj® (revumenib) Wins Prestigious 2026 Prix Galien USA Award for Best Product for Rare/Orphan DiseasesOct 30, 2026 · finance.yahoo.com
- Syndax Announces Participation in November Investor ConferencesOct 30, 2026 · finance.yahoo.com
- Earnings Preview: Niagen Bioscience (NAGE) Q3 Earnings Expected to DeclineOct 28, 2026 · finance.yahoo.com
- Syndax Pharmaceuticals (SNDX) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseOct 26, 2026 · finance.yahoo.com
- Syndax to Announce Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 2, 2026Oct 26, 2026 · finance.yahoo.com
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals, Inc. (SNDX) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.